Anti-PD-1 therapy achieves favorable outcome in gastric cancer combined with chronic hepatitis B

Anti-PD-(L)1 immunotherapy may be safe and effective in gastric cancer patients with HBV infection. CHB patients are more likely to have lasting benefits than are HBV- patients and RHB patients. This may be attributed to alterations in the immune microenvironment in patients, and future studies should further explore the relevant mechanisms involved. CHB patients may have a more inflamed immune microenvironment, leading to enhanced ICI efficacy.